New targeted drug shows promise for Hard-to-Treat stomach cancers
NCT ID NCT05980416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new drug called EO-3021, which targets a protein (CLDN18.2) found on some cancer cells. The study included 88 adults with advanced stomach or gastrointestinal cancers that had not responded to standard treatments. Participants received EO-3021 alone or combined with other drugs to check safety and early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EO-3021 (antibody drug conjugate targeting CLDN18.2)
- What this could lead to
- If successful, this could lead to a new treatment option for advanced stomach and gastrointestinal cancers that express CLDN18.2.
- What could go wrong
- This is an early Phase 1 trial focused on safety, so it may not show strong anti-cancer effects. The trial was terminated, and results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health/Wake Forest University
Charlotte, North Carolina, 28204, United States
-
City of Hope
Duarte, California, 91010, United States
-
Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Henry Ford Cancer
Detroit, Michigan, 48202, United States
-
Johns Hopkins University - Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Samsung Medical Center
Seoul, South Korea
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
UW Carbone Cancer Center - Cancer Connect
Madison, Wisconsin, 53792, United States
-
Yale - Smilow Cancer Hospital
New Haven, Connecticut, 06519, United States
-
Yonsei University
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill slow brain tumor growth after surgery?
- Liver tumors targeted directly: old pump, new drug
- Time-Restricted eating may ease lingering cancer fatigue
- Emotional support may ease distress during cancer genetic testing
- New drug velzatinib tested for Hard-to-Treat stomach and intestinal tumors
- AI could outshine standard tumor measurements to predict survival